This Phase I intervention trial (n=120) investigates whether stimulating the serotonin system influences pro-social behaviour compared to stimulating the dopamine system in healthy individuals; single-dose psilocybin (15 mg), MDMA (100 mg) or methylphenidate (60 mg) in a double-blind randomized parallel design.
Randomized, double-blind, single-center, parallel-group Phase I study in healthy volunteers comparing single doses of psilocybin (15 mg), MDMA (100 mg) and methylphenidate (60 mg) to investigate pro-social cognition.
Objective, ecologically valid measures of pro-social behaviour will be assessed acutely and at four weeks to determine lasting and pharmacology-specific effects; safety and tolerability monitored by standard clinical and laboratory measures.
Single oral dose psilocybin (capsule), 40 participants.
Oral capsule
Single oral dose MDMA (capsule), 40 participants.
Oral capsule
Single oral dose methylphenidate, 40 participants.
Methylphenidate 60 mg (encoded as non-psychedelic comparator)